HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
ARVN
Arvinas Inc
Healthcare Biotechnology · Connecticut, USA · Reports in usd
Market Cap: $656.4M
Market Cap
$656.4M
Enterprise Val
-$20.1M
P/E Ratio
-8.12
P/B Ratio
1.51
Trailing PEG (1Y)
-0.16
As Of
Apr 27, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$433.9M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-14.25%
Return on Assets-9.31%
Current Ratio4.92
Debt/Equity0.02
LT Debt/Equity0.02
Revenue Per Share0.15

Income Statement

Dec 31, 2025
Revenue$9.5M
Cost of Revenue$0.00
Gross Profit$9.5M
R&D$61.1M
SG&A$23.0M
Operating Expenses$84.1M
Operating Income-$74.6M
Interest Expense$0.00
Tax Expense$200.0K
Net Income-$67.4M
EPS (Basic)$-0.96
EPS (Diluted)$-0.96
EBIT-$67.2M
EBITDA-$66.0M
Consolidated Income-$67.4M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$142.9M
Accounts Receivable$6.4M
Inventory$0.00
Current Assets$700.7M
LT Investments$0.00
Property, Plant & Equipment$13.4M
Intangibles$0.00
Non-Current Assets$17.2M
Total Assets$717.9M
Accounts Payable$69.5M
Current Debt$1.7M
Current Liabilities$142.5M
LT Debt$7.2M
Non-Current Liabilities$141.5M
Total Liabilities$284.0M
Total Debt$8.9M
Retained Earnings-$1.61B
Shareholder Equity$433.9M
Shares Outstanding64,224,294

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$30.4M
Investing Cash Flow$145.8M
Financing Cash Flow-$74.0M
CapEx-$200.0K
Free Cash Flow-$30.6M
Depreciation & Amort.$1.2M
Stock-Based Comp$8.5M
Acquisitions / Disposals$0.00
Investment Activity$146.0M
Debt Issued/Repaid-$100.0K
Equity Issued/Repaid-$73.9M
Dividends Paid$0.00
Net Change in Cash$41.4M
Data cached · Meta live · Daily live · Statements live · TTL 24h